Cancer Detection by Immunoscintigraphy, Selection, and Clinical Application of Monoclonal Anti-CEA Antibodies and Their F (ab′)2 or Fab Fragments

A number of assays are currently under evaluation for their potential usefulness in the selection of new chemotherapeutic agents or as predictive indicators for use in the design of optimal cancer treatment. Assays fall under the general categories of tumor cell survival, treatment-induced cellular damage, and determination of inherent tumor factors which includes tumor cell kinetics, tumor oxygenation, and measurement of specific biochemical systems. While technical advances to optimize these assays are continuing, possible inter- and intra-tumor cell variability to anticancer treatment modalities may complicate the interpretation and subsequent use of these assays. Regardless of their ultimate usefulness as clinical predictors, these assays will be extremely valuable in better characterizing and understanding the cell biology and biochemistry of human malignancies.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cancer Detection by Immunoscintigraphy, Selection, and Clinical Application of Monoclonal Anti-CEA Antibodies and Their F (ab′)2 or Fab Fragments

Cited by 3 publications

References 11 publications

New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma

New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma

What's New in Tumor Markers and their Measurements?

Potential Applicability of Nonclonogenic Measurements to Clinical Oncology

Contact Info

Product

Resources

About